Radiopharm Theranostics Reports Positive RAD 101 Phase 2b Results; Raises $12.5M
Radiopharm Theranostics reported positive Phase 2b clinical trial results for its imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint, and plans to initiate a Phase 3 trial in Q4 2026. The company also announced it raised approximately $12.5M through an institutional offer and launched a $6M Share Purchase Plan post-quarter end. For the quarter ended June 30, 2026, net cash outflows from operating activities were $14.97M, with closing cash at $4.1M, though the company received a $5.9M R&D Tax Incentive post-quarter.
Key Highlights
- RAD 101 Phase 2b trial met primary endpoint with 93% of patients achieving it.
- Company plans to initiate Phase 3 registrational trial for RAD 101 in Q4 2026.
- Raised approximately $12.5M through an institutional offer post-quarter end.
- Launched a $6M Share Purchase Plan, with $3M already subscribed post-quarter end.
- Net cash outflows from operating activities for the quarter were $14.97M.
- Closing cash and cash equivalents at quarter end (June 30, 2026) was $4.1M.
- Received FY25 Australian R&D Tax Incentive of $5.9M post-quarter end.
- RAD 204 Phase 1 study showed RECIST-confirmed Partial Response in one patient.
Price Impact
More from RADX
Radiopharm Theranostics RAD101 Phase 3 Trial Set for 1Q27; RAD301 Data Positive
Radiopharm Theranostics Seeks Approval for $18.5M Capital Raise
Radiopharm RAD 101 Phase 2b Positive; 93% Met Endpoint; Raises $12.5M